<code id='2CD36E93AB'></code><style id='2CD36E93AB'></style>
    • <acronym id='2CD36E93AB'></acronym>
      <center id='2CD36E93AB'><center id='2CD36E93AB'><tfoot id='2CD36E93AB'></tfoot></center><abbr id='2CD36E93AB'><dir id='2CD36E93AB'><tfoot id='2CD36E93AB'></tfoot><noframes id='2CD36E93AB'>

    • <optgroup id='2CD36E93AB'><strike id='2CD36E93AB'><sup id='2CD36E93AB'></sup></strike><code id='2CD36E93AB'></code></optgroup>
        1. <b id='2CD36E93AB'><label id='2CD36E93AB'><select id='2CD36E93AB'><dt id='2CD36E93AB'><span id='2CD36E93AB'></span></dt></select></label></b><u id='2CD36E93AB'></u>
          <i id='2CD36E93AB'><strike id='2CD36E93AB'><tt id='2CD36E93AB'><pre id='2CD36E93AB'></pre></tt></strike></i>

          Home / knowledge / hotspot

          hotspot


          hotspot

          author:focus    Page View:79477
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In